The contrast agent "Iodine sea alcohol injection" introduced by Heng Rui last month is about to be approved.

On June 10, the State Drug Administration showed that Hengrui's new application for the market of the newly introduced contrast agent, iody haiol injection, entered the "in approval" status in May and was about to be approved for listing.
another contrasting agent, iodypaol, introduced at the same time, was approved for sale a month ago. On May 12,
, Hengrui announced the signing of a cooperation agreement with Zhejiang Shitaili and Shanghai Shi Taili (co-named Staili) on the production, supply and commercial operation of the two products.
Hengrui will be responsible for the commercialization of co-products (iody seaalcohol injections and iodypaol injections) in Chinese mainland, including marketing, self-marketing or co-marketing with distributors.
Hengrui should provide its own brand and trademarks for the sale of co-production products, the sale of the full amount of Hengrui.
, The Pacific Will supply Heng Rui exclusively to the cooperative products in the agreed area, and shall not supply or sell the cooperative products to other third parties, or any other product seinier.
Zhejiang Shitaili will sell raw materials (raw material prices should not be higher than the lowest price of Zhejiang Shitaili to sell the same quality raw materials to other third parties in the field in the current month) to Shanghai Shi taili, by Shanghai Shitaili in accordance with the manufacturing cost pricing to Hengrui sales of cooperative products.
Hengrui agreed to pay the manufacturing cost price to Shanghai State Corporation at the agreed time.
contrast agent leading such as tiger-wing iodine sea alcohol injection and iodine paol injection are X-ray contrast agent products, in 2019 Hengrui contrast agent achieved revenue of 3.23 billion yuan, up nearly 39% YoY, currently sitting in the domestic contrast agent market accounted for the first throne;
Hengrui through cooperation to obtain iodine sea alcohol and iodized paol, no doubt to consolidate its contrast agent's domestic market position. according to public data
, iodized sea alcohol in 2017 sample hospital sales of 680 million yuan, iodine contrast agent market share of the second largest (after the market share of iodized salsaol);
Insight database shows that there are currently 57 iodine sea alcohol injections approved for sale and in use, involving Ningbo Tianheng Pharmaceuticals, General Electric Pharmaceuticals, Hunan Jinjian Pharmaceuticals, Shanghai Xudonghai Pu Pharmaceuticals, Huaren Pharmaceuticals, Hunan Hansen Pharmaceuticals, Chenxin Pharmaceuticals, Guizhou Bailing Enterprise Group Pharmaceuticals, Beijing Beilu Pharmaceuticals Among them, 11 enterprises, such as Yangzijiang Pharmaceuticals and Zhejiang Tianrui Pharmaceuticals, only 6 of which have obtained the approval number of API, namely, Zhejiang Shitaili Pharmaceuticals, Zhejiang Taizhou Haishen Pharmaceuticals, Zhejiang Haichang Pharmaceuticals, Beijing Beilu Pharmaceuticals, Zhejiang Anlikang Pharmaceutical Stakes, Guizhou Jingfeng Injection Co., Ltd.
Hengrui this cooperation to choose the API and preparations have advantages of the Teri, can be said to be a wise move.
with the help of Heng Rui's leading position of the creation agent, coupled with domestic sales promotion strength, the cooperation between the two sides can be described as a win-win strategy.
original title: HengRui / Teri co-operative varieties "iodine sea alcohol injection" will soon be approved.